Moderna says it's reached the required number of Covid-19 cases for its first interim analysis. When is the readout coming?
Pfizer and BioNTech came out with the first Phase III interim analysis of their Covid-19 vaccine earlier this week, and it appears Moderna is right on their heels.
The Cambridge, MA-based biotech announced Wednesday afternoon that it has reached the threshold required to conduct its own initial Phase III interim analysis. And as a result of a “significant increase” in trial participants contracting confirmed cases of Covid-19, Moderna also expects the analysis will include “substantially more” than the 53 cases originally set out for the analysis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,600+ biopharma pros reading Endpoints daily — and it's free.